@article{Beck2012,
	title = {Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry},
	volume = {84},
	issn = {0003-2700},
	url = {http://pubs.acs.org/doi/abs/10.1021/ac3002885},
	doi = {10.1021/ac3002885},
	abstract = {This Feature will introduce the strategies of therapeutic antibodies (mAbs) in-depth characterization by mass spectrometry (MS) and discuss analytical comparison of biosimilar to originator mAbs, with the cases of trastuzumab and cetuximab. In addition, the structural and functional insights gained both by state-of-the art and emerging MS methods used for biobetters and next generation antibodies design and optimization will also be highlighted.},
	number = {11},
	journal = {Analytical Chemistry},
	author = {Beck, Alain and Sanglier-Cianférani, Sarah and Dorsselaer, Alain Van},
	month = jun,
	year = {2012},
	pmid = {22510259},
	note = {tex.ids= beckBiosimilarBiobetterNext2012
ISBN: 1520-6882 (Electronic)0̊003-2700 (Linking)},
	pages = {4637--4646},
}

{"_id":"QrvWpLANTnqwdCFZk","bibbaseid":"beck-sangliercianfrani-dorsselaer-biosimilarbiobetterandnextgenerationantibodycharacterizationbymassspectrometry-2012","author_short":["Beck, A.","Sanglier-Cianférani, S.","Dorsselaer, A. V."],"bibdata":{"bibtype":"article","type":"article","title":"Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry","volume":"84","issn":"0003-2700","url":"http://pubs.acs.org/doi/abs/10.1021/ac3002885","doi":"10.1021/ac3002885","abstract":"This Feature will introduce the strategies of therapeutic antibodies (mAbs) in-depth characterization by mass spectrometry (MS) and discuss analytical comparison of biosimilar to originator mAbs, with the cases of trastuzumab and cetuximab. In addition, the structural and functional insights gained both by state-of-the art and emerging MS methods used for biobetters and next generation antibodies design and optimization will also be highlighted.","number":"11","journal":"Analytical Chemistry","author":[{"propositions":[],"lastnames":["Beck"],"firstnames":["Alain"],"suffixes":[]},{"propositions":[],"lastnames":["Sanglier-Cianférani"],"firstnames":["Sarah"],"suffixes":[]},{"propositions":[],"lastnames":["Dorsselaer"],"firstnames":["Alain","Van"],"suffixes":[]}],"month":"June","year":"2012","pmid":"22510259","note":"tex.ids= beckBiosimilarBiobetterNext2012 ISBN: 1520-6882 (Electronic)0̊003-2700 (Linking)","pages":"4637–4646","bibtex":"@article{Beck2012,\n\ttitle = {Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry},\n\tvolume = {84},\n\tissn = {0003-2700},\n\turl = {http://pubs.acs.org/doi/abs/10.1021/ac3002885},\n\tdoi = {10.1021/ac3002885},\n\tabstract = {This Feature will introduce the strategies of therapeutic antibodies (mAbs) in-depth characterization by mass spectrometry (MS) and discuss analytical comparison of biosimilar to originator mAbs, with the cases of trastuzumab and cetuximab. In addition, the structural and functional insights gained both by state-of-the art and emerging MS methods used for biobetters and next generation antibodies design and optimization will also be highlighted.},\n\tnumber = {11},\n\tjournal = {Analytical Chemistry},\n\tauthor = {Beck, Alain and Sanglier-Cianférani, Sarah and Dorsselaer, Alain Van},\n\tmonth = jun,\n\tyear = {2012},\n\tpmid = {22510259},\n\tnote = {tex.ids= beckBiosimilarBiobetterNext2012\nISBN: 1520-6882 (Electronic)0̊003-2700 (Linking)},\n\tpages = {4637--4646},\n}\n\n","author_short":["Beck, A.","Sanglier-Cianférani, S.","Dorsselaer, A. V."],"key":"Beck2012","id":"Beck2012","bibbaseid":"beck-sangliercianfrani-dorsselaer-biosimilarbiobetterandnextgenerationantibodycharacterizationbymassspectrometry-2012","role":"author","urls":{"Paper":"http://pubs.acs.org/doi/abs/10.1021/ac3002885"},"metadata":{"authorlinks":{}},"html":""},"bibtype":"article","biburl":"https://bibbase.org/zotero/eric.larG4","dataSources":["4i5C7S78DvJNsaHyg","5L2zM5wNE5CBYNuea"],"keywords":[],"search_terms":["biosimilar","biobetter","next","generation","antibody","characterization","mass","spectrometry","beck","sanglier-cianférani","dorsselaer"],"title":"Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry","year":2012}